NC
FOLD

nVerses Capital’s Amicus Therapeutics FOLD Stock Holding History

nVerses Capital’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-17,500
Closed -$187K – 316
2024
Q3 		$187K Buy
+17,500
New +$191K 0.09% 345
2024
Q2 		– Sell
-5,600
Closed -$66K – 1070
2024
Q1 		$66K Buy
+5,600
New +$71.6K 0.16% 230

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

nVerses Capital's FOLD Position: Q4 2024 in Review

nVerses Capital sold out of Amicus Therapeutics (FOLD) in Q4 2024, closing a stake of 17,500 shares — an estimated $187K sold.

nVerses Capital first reported a position in FOLD in Q1 2024 and held it in 2 quarters. The position peaked at $187K in Q3 2024. 290 funds tracked by Wall St. Rank hold FOLD as of Q4 2024.

  • nVerses Capital reported no remaining Amicus Therapeutics position as of Q4 2024 after selling out during the quarter.
  • nVerses Capital sold 17,500 Amicus Therapeutics shares in Q4 2024, an estimated $187K.
  • nVerses Capital first reported a position in Amicus Therapeutics in Q1 2024 and held it in 2 quarters.
  • nVerses Capital's Amicus Therapeutics position peaked at $187K in Q3 2024.
  • 290 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2024.

Based on nVerses Capital's 13F filing for Q4 2024.